Novel agents for advanced pancreatic cancer

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinleye, Akintunde, Iragavarapu, Chaitanya, Furqan, Muhammad, Cang, Shundong, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741843/
https://www.ncbi.nlm.nih.gov/pubmed/26369833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741843/
https://www.ncbi.nlm.nih.gov/pubmed/26369833

Ejemplares similares